Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study

Fig. 2

Kaplan-Meier curves for overall survival. The median overall survival was 17.7 months (95% confidence interval [CI], 15.2–18.3) for PLH and 12.6 months (95% CI, 11.1–13.7) for PL (HR 0.52, 95%CI, 0.36–0.75; p = 0.001). *The hazard ratio was calculated using a Cox proportional hazards model, with the age, ECOG performance status, time since diagnosis, HCC aetiology, Child-Pugh A or B, Liver cirrhosis, PD-L1 expression, tumor thrombus, central nervous system metastasis, and number of metastatic sites used as covariates and therapy as the time-dependent factor

Back to article page